Is Elevated Neutrophil Count and Neutrophil-to-Lymphocyte Ratio a Cause or Consequence of Schizophrenia?—A Scoping Review

Asbjørn Arnesen Sandberg¹, Vidar M. Steen¹,² and Anja Torsvik¹,²*

¹ Norwegian Centre for Mental Disorders Research (NORMENT), Department of Clinical Science, University of Bergen, Bergen, Norway, ² Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway

Background: Several studies have found an association between elevated neutrophil count or neutrophil-to-lymphocyte ratio (NLR) in peripheral blood from patients with schizophrenia. The etiology behind this effect is unknown, and it is unclear if changes in neutrophil count and NLR may be induced by antipsychotics or if these parameters relate to the diagnosis and symptoms of schizophrenia. The purpose of this scoping review was to map research that explores this association, and to identify gaps in the current knowledge base.

Method: The work was conducted in accordance with established methodological standards for scoping reviews. Studies on neutrophil count and NLR in schizophrenia were identified through search in relevant databases, and a parallel screening procedure was performed to ensure validity and reproducibility of the search. Articles that included different comparison groups, with differences in medication status (drug-naïve or drug-free vs. medicated), current disease state (relapse vs. remission), or treatment response, were included, as well as studies evaluating the association between symptomatology and neutrophil count or NLR.

Results: The available literature was limited with substantial differences in aims, methods, and outcomes. In total, 13 articles were included for the synthesis of this review. Some interesting trends were identified: Neutrophil count and NLR seem to be elevated in schizophrenia patients regardless of current or past use of antipsychotic therapy. Neutrophil count and NLR correlated significantly with positive symptoms of schizophrenia. Still, these findings should be interpreted with caution due to considerable methodological differences and weaknesses in the literature, particularly concerning the blood sampling procedure.

Conclusion: By including longitudinal studies and by comparing patient groups based on medication status, disease state and response, our study provides a basis for dissecting the associations between increased neutrophil count or NLR and a diagnosis of schizophrenia. Further research should investigate and quantify the apparent strong correlation between neutrophil count or NLR and positive symptoms in schizophrenia, to evaluate its clinical potential to guide diagnostics, treatment, or as a predictor...
INTRODUCTION
The immune system and its relation to psychosis is a field with emerging interest. Epidemiological studies have shown that individuals diagnosed with schizophrenia have a higher prevalence of autoimmune diseases and infections compared to the general population (1–3). Alterations in various immune factors have been demonstrated by genetic analyses, and elevated levels of pro-inflammatory cytokines and CRP have been reported in schizophrenia vs. healthy controls (4–7). Of particular interest, recent meta-analyses have reported increased neutrophil count in patients with schizophrenia as compared to controls (8–10). Neutrophil-to-lymphocyte ratio (NLR) is another parameter that has received growing attention with respect to the inflammatory hypothesis of schizophrenia. NLR is frequently used as a marker of the balance between two immune pathways: the innate immune system through neutrophil granulocytes, and the adaptive immune system through the lymphocytes. High NLR has been found to correlate with increased levels of cytokines and CRP, and it is used increasingly in the literature as a proxy for systemic inflammation. A correlation between NLR and pro-inflammatory cytokines has been reported for ovarian cancer (11), liver cirrhosis (12), and laryngeal cancer (13). As a predictor, increased NLR is found to correlate with short- and long-term mortality in cardiac diseases and in cancer (14, 15). Also schizophrenia patients seem to have increased NLR compared to healthy controls (9, 10). However, the causality of increased neutrophil count, NLR and other immune markers is not established, and the potential clinical utility of such findings remain to be determined.

In this review, we focus on published studies that shed light on the etiology of altered neutrophil count and NLR in schizophrenia. As the observed associations between schizophrenia and neutrophils or NLR are far from fully understood, with a limited research database, we have chosen a scoping review approach to examine and map the quantity, the variety, and the characteristics of available research on this topic (16). Scoping reviews are particularly suited for issues that need investigation and understanding of larger concepts, and where the knowledge database is heterogeneous in research aim, methodology, and outcome.

Our main question is: Are changes in neutrophil numbers in schizophrenia related to the disease state or the antipsychotic medication? To touch upon this issue, we have defined several sub-questions to be addressed:

1. How does neutrophil count and NLR relate to the diagnosis of schizophrenia?

2. What is the effect of antipsychotic drug treatment on neutrophil count and NLR?
   a. Is neutrophil count or NLR different in first episode psychosis (FEP) or drug-naïve or drug-free patients compared to healthy controls?
   b. Is neutrophil count or NLR different between medicated and unmedicated patients?
   c. Is neutrophil count or NLR different between responders and non-responders?

3. How does neutrophil count and NLR associate with symptoms and the state of the disease?
   a. Is neutrophil count or NLR different between relapse and remission phase?
   b. Is neutrophil count or NLR associated with disease symptoms scores?

To address these questions, we aimed at including studies that compare FEP to controls and chronic schizophrenia patients, drug-naïve to medicated schizophrenia patients, as well as patients in relapse to patients in remission. In addition, we explored available research data on the changes in neutrophil numbers and NLR and their relation to symptoms score [The Positive and Negative Syndrome Scale (PANSS) score or equivalent]. The variables to be compared were neutrophil count and NLR. The purpose was to map existing literature that can contribute to improve our understanding of the causality of the neutrophil alterations in schizophrenia, as well as to identify potential gaps in the knowledge base.

METHOD
This scoping review is conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR) recommendations (16). PRISMA-ScR provides guidelines for a systematic, reproducible, and transparent method of conducting and reporting scoping reviews. The PRISMA-ScR-checklist is provided in Supplementary Table 1.

Search Strategy
The search was conducted through PubMed, Web of Science and PsycInfo, on 9 September 2020 with a repeated search on 7 June 2021 to check for studies published after the first search. Adjusted to the different bibliographic styles, the following combinations of outcome. This review also exposes important methodological weaknesses in the literature on neutrophil count and NLR measurements. Standardization of blood sampling and processing is crucial to reduce bias, and factors that are known to influence leukocyte levels need to be accounted for.

Keywords: neutrophil, neutrophil-to-lymphocyte, NLR, schizophrenia, FEP, antipsychotic, psychosis
of search terms were used: “Neutrophils” OR “Neutrophil-to-
lymphocyte” OR “NLR” AND “Schizophrenia” OR “Psychosis.”
References from selected articles were also screened, to identify
additional sources.
Inclusion criteria were studies that assessed neutrophil count
or NLR in schizophrenia patients or FEP patients. Articles that
only assessed granulocyte count were also included, considering
that neutrophils constitute the majority of the granulocytes. To
be included in the scoping review, the articles should also include
either longitudinal measurements, with minimum one baseline
and one follow-up measurement, or relevant comparison groups.
The comparison groups of interest were studies comparing
different drug classes (first-generation vs. second-generation
antipsychotics etc.), medication status (drug-naïve or drug-
free vs. medicated), current disease state (first episode vs.
relapse vs. remission), or treatment response (responders vs.
non-responders). Studies that analyzed the correlation between
neutrophil count or NLR and symptoms score (by PANSS or
equivalent) were also included.
Exclusion criteria were: wrong population (other diagnosis
than schizophrenia or FEP, in vitro and in vivo studies), wrong
publication type (case reports, reviews, meta-analyses, guidelines,
letters, commentaries), wrong outcome (other measures than
neutrophil count and NLR), and wrong study design (cross-
sectional case-control studies with no comparisons related to
medication use or disease state). Lastly, studies where full-text
article could not be obtained, as well as non-English articles, were
excluded from this review. Date of publication was not a criterion
for exclusion.
A blinded literature screening was conducted in parallel by
the first author and the senior author, to ensure reproducibility
of the search. For this purpose, we used Rayyan, a web tool
developed for literature screening in systematic reviews (17).
Initial screening was based on title and abstract screening.
Disagreement regarding inclusion/exclusion was resolved
during discussion and consensus. The complete screening
process is summarized in Figure 1.
We grouped the studies based on the type of information they
unveiled, and their respective focus (Table 1).
Although scoping reviews do not require a formal quality
evaluation of included articles, we found it appropriate to
evaluate certain methodological parameters. Description of study
participants (Supplementary Table 1) and differences in blood
sampling procedure (Table 2) were reviewed, as variation within
these factors could potentially constitute a significant source of
error when analyzing data on neutrophil count and NLR.
RESULTS
The literature search yielded 525 hits in total, after duplicates
and non-English articles were removed. An initial parallel
abstract screening resulted in 97.1% correspondence in
inclusion/exclusion. We excluded 466 studies due to wrong
study population (e.g., other patient groups, in vivo and in
vitro studies), wrong publication type (e.g., reviews and case
reports), and wrong outcome measures (Figure 1). A final
screening resulted in 49 articles being proceeded to full-text
eligibility assessment and further evaluation. Two could not
be retrieved and 27 were discarded because of wrong study
design (e.g., cross-sectional case-control studies, intervention
studies, mixed diagnostic group, or wrong comparison groups).
There was disagreement regarding seven articles. These were
clozapine studies, and we decided to exclude them due to
clozapine's potential to induce neutropenia. Thirteen articles
met all inclusion criteria and were used for the synthesis of
this review. An overview of the included studies is displayed in
Table 1.
In summary, 12 studies were case-control studies, and one
was a randomized controlled trial (RCT). Five of the 13 articles
contained longitudinal measurements. Twelve of the included
articles were published between 2014 and 2020, the remaining
article was published in 1998. The number of participants ranged
from 22 to 1,144, with a total of 3,977 study participants. Four
studies had <100 participants and seven studies had more than
200 participants.
Table 2 gives an overview of the blood sampling procedures.
Seven out of 13 studies clearly stated that blood sampling was
done at admittance, however, the time frame differed from within
24 h to 3 days or was not specified. Only five studies confirmed
the fasting status of the participants, and only four studies
reported the time of day of blood sampling.
How Does Neutrophil Count and NLR
Relate to the Diagnosis of Schizophrenia?
To exclude the potential effect of medication, we first wanted
to investigate if neutrophil count and NLR differ in drug-
naïve or drug-free patients compared to healthy controls. We
identified three studies comparing FEP-patients to healthy
controls or reference values (23, 25, 26) and one that compared
early-onset schizophrenia to controls (30). Núñez et al. found
a significantly elevated neutrophil count in FEP patients
compared to healthy controls (23). However, in this study
blood sampling was not consistently drawn at admission.
Some were sampled at 2 months follow-up, which implies
a mix of medicated and unmedicated patients, and thus
not a pure drug-naïve patient group to be compared with
healthy controls.
Stefanović et al. compared granulocyte count in drug-
naïve FEP-patients to a statistical reference for hematological
parameters, and found that 41% of the patients had elevated
granulocyte values at admission (25). Similar findings were
reported by Steiner et al. (26). Blood counts at admission
showed significantly higher neutrophil counts and NLR in
drug-naïve FEP-patients and chronic drug-free schizophrenia
patients compared to healthy controls, with 23% of the
FEP and 30% of chronic schizophrenia patients having
neutrophil count above the reference range, compared
to 6% in the healthy controls. There was no significant
difference between the various patient groups with respect to
neutrophil numbers.
A study on early-onset schizophrenia also showed that
patients had higher neutrophil count and NLR compared to age-
and sex-matched controls (30), however, the study did not report if patients were on medication.

**Does Antipsychotic Drug Treatment Affect the Neutrophil Count and NLR?**

To investigate the effect of antipsychotic medication on neutrophil count and NLR, we looked for longitudinal studies that followed patients before and after treatment, and studies that compared groups of medicated and drug-free patients. Six studies investigated the effect of antipsychotics on neutrophil numbers (Table 3). Three studies had longitudinal measurements (25, 26, 31), the others were cross-sectional (21, 24, 27). One study included a comparison based on antipsychotic response (25).

Among the cross-sectional studies, three studies found no significant difference in neutrophil count and NLR between drug-naïve or drug-free patients compared to medicated patients (24, 26, 31). However, the largest study, with 1,144 participants, found significantly higher neutrophil count and NLR in drug-free patients compared to those that had received antipsychotic therapy (27).

Different study designs were used to assess the effect of antipsychotic treatment in longitudinal studies: Steiner et al. reported a significant reduction in neutrophil count for FEP-patients (11%) and chronic schizophrenia patients (17%) after 6 weeks on antipsychotic therapy, compared to baseline measurements (26). Further analyses showed that olanzapine correlated negatively with alteration in neutrophil count in FEP-patients. Stefanović et al. divided the patients into three groups based on which antipsychotic regimen was used: first-generation antipsychotics (FGA), second-generation antipsychotics (SGA) or combined antipsychotic medication (FGA + SGA) (25). In the groups with either FGA or SGA, a significant reduction of granulocytes was found after 4 weeks of treatment. Kovács et al. compared NLR in schizophrenia patients on the basis of the length of the antipsychotic treatment (21). One group of short-term treated patients (average 3.5 ± 1.9 weeks) was
compared to a group of long-term treated patients (average 8.8 ± 5.9 years). Patients on long-term antipsychotic therapy had significantly lower NLR compared to patients on short-term therapy.

Only one study grouped patients based on their response to antipsychotic treatment (25). Response was defined as at least 50% reduction of total PANSS-score. At 4 weeks follow-up, there was no difference in granulocyte count between responders and non-responders.

### How Does Neutrophil Count and NLR Associate With Symptoms and the State of the Disease?

To investigate if neutrophil count and NLR might be associated with the state of the disease, we looked at articles that compared patients in relapse vs. remission, and studies that investigated the association with symptoms score.

In total, three articles, two longitudinal and one cross-sectional study, included NLR measurements at different disease stages of schizophrenia (Table 3). The two longitudinal studies showed a significant decrease in NLR from psychosis to remission (20, 31). However, when a group of schizophrenia patients in acute exacerbation was compared with a group of patients in remission, no significant difference in NLR was found (19).

Nine studies explored the relationship between neutrophil count or NLR and psychosis symptoms score. Six studies used PANSS, two used the Brief Psychiatric Rating Scale (BPRS) (24, 27), and one used items from BPRS in combination with The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS) (29). Two studies also used the Clinical Global Impression-Severity scale (CGI-S).

Four studies revealed a significant association between neutrophil status and PANSS-total [Table 3; (21–23, 26)], and this was driven by a positive correlation with PANSS-P but not PANSS-N.

In a longitudinal study by Zorrilla et al. antipsychotic-naive or antipsychotic-withdrawn schizophrenia patients were followed for 6 months (29). The authors found a correlation between relative lymphocyte and granulocyte numbers at intake to subsequent reductions in positive symptoms. More specifically, patients with a profile of lymphopenia and granulocytosis at intake had less than two-thirds reduction in SAPS-scores, while patients with normal lymphocyte and granulocyte counts at admission improved with more than two-thirds reduction in SAPS-scores.

Contrary to these findings, four studies found no correlation between neutrophil numbers and symptoms score (24, 27, 28, 30). However, Zhou et al. found that in drug-free patients, NLR was significantly associated with CGI-S and the BPRS total score,

### References

TABLE 1 | Included articles for this scoping review with information about study participants and comparison groups.

| References          | Type of study                      | Longitudinal | FEP | Comparison groups                          | Healthy controls | NLR | Neutrophil count | No. of participants |
|---------------------|------------------------------------|--------------|-----|--------------------------------------------|------------------|-----|------------------|---------------------|
| Balcioğlu and Karlıoglu (19) | Retrospective cross-sectional case-control | No            | No  | Relapse vs. remission                      | Yes              | Yes | No               | 1,063               |
| Bustan et al. (20)   | Retrospective cross-sectional case-control | Yes          | No  | Relapse vs. remission                      | No               | Yes | No               | 366                 |
| Kovács et al. (21)   | Cross-sectional cohort             | No            | No  | Symptomatology                             | No               | Yes | No               | 22                  |
| Kulaksızoglu and Kulaksızoglu (22) | Cross-sectional case-control | No            | No  | Symptomatology                             | Yes              | Yes | Yes              | 125                 |
| Nünez et al. (23)    | Multicenter cross-sectional case-control | Yes          | Yes | Drug-free vs. medicated, relapse vs. remission, symptomatology | Yes              | No  | Yes              | 218                 |
| Semiz et al. (24)    | Multicenter cross-sectional case-control | No            | No  | Drug-free vs. medicated, before vs. after antipsychotics use, symptomatology | Yes              | Yes | Yes              | 245                 |
| Stefanović et al. (25) | Randomized trial                  | Yes          | Yes | Drug-free vs. medicated, before vs. after antipsychotics use, symptomatology | No               | No  | No               | 78                  |
| Steiner et al. (26)  | Case-control                       | Yes          | Yes | Drug-free vs. medicated, before vs. after antipsychotics use, symptomatology | Yes              | Yes | Yes              | 547                 |
| Zhou et al. (27)     | Retrospective case-control cohort  | No            | No  | Drug-free vs. medicated, symptomatology     | No               | Yes | Yes              | 1,144               |
| Yüksel et al. (28)   | Cross-sectional case-control       | No            | No  | Symptomatology                             | Yes              | Yes | Yes              | 105                 |
| Zorrilla et al. (29) | Case-control                       | Yes          | No  | Symptomatology                             | Yes              | No  | No               | 99                  |
| Arif Önder et al. (30) | Retrospective case-control         | No            | No  | Symptomatology                             | Yes              | Yes | Yes              | 64                  |
| Özdin and Böke (31)  | Retrospective case-control         | Yes          | No  | Drug-free vs. medicated, relapse vs. remission, before vs. after antipsychotics use | Yes              | Yes | No               | 210                 |

September 2021 | Volume 12 | Article 728990

Frontiers in Psychiatry | www.frontiersin.org
while in medicated patients NLR was negatively associated with the BPRS negative symptoms score (27).

DISCUSSION

To follow up on former studies that have shown increased neutrophil count and NLR in patients with schizophrenia compared to healthy controls, we made a broad systematic approach to determine if the neutrophil numbers or NLR in schizophrenia reflects the disease state or if it is a medication effect. Through different formulated sub-questions, we identified some interesting trends.

We first asked how neutrophil count and NLR relate to the diagnosis of schizophrenia. Four studies reported higher neutrophil counts in FEP or early-onset schizophrenia compared to healthy controls, indicating that this is a presenting feature of untreated disease (23, 25, 26, 30). This is in agreement with three recent meta-analyses (8–10).

We next explored the effect of antipsychotics on neutrophil count and NLR. One recent cross-sectional retrospective study reported higher neutrophil numbers in drug-free schizophrenia patients compared to medicated patients (27), while three other cross-sectional studies reported no difference between medicated, antipsychotic-withdrawn and antipsychotic-naive schizophrenia patients (24, 26, 31). A possible explanation of this controversy is that neutrophil numbers decrease over time during antipsychotic drug exposure, as demonstrated on short-term compared to long-term antipsychotic treated patients (21) and in longitudinal studies (25, 26). This time-dependent decrease in neutrophil numbers postulates two different explanations: Neutrophil numbers may be directly decreased by antipsychotics, or indirectly by processes involved in the decrease of symptoms.

Finally, we asked how neutrophil count and NLR is associated with symptoms and the state of the disease. NLR significantly decreased when patients changed from relapse to remission (20, 31). Moreover, four of five studies found positive correlation between PANSS total score and neutrophil count or NLR. Of note, in the study that did not report correlation with PANSS (30), the patients had lower total symptoms burden than the patients in the other studies (21–23, 26). This indicates that the neutrophil numbers and NLR may be a state marker for disease severity or disease phase in schizophrenic patients, rather than an effect of antipsychotics. Interestingly, no study found correlation to

---

**TABLE 2 | Blood sampling information in the included articles.**

| References                        | SAMPLING INFO                  | METHODOLOGY                           |
|-----------------------------------|--------------------------------|---------------------------------------|
|                                   | Time of blood sampling          | Fasting status                        | Anticoagulant | Time between sampling and analysis | Blood cell count method |
| Balcioglu and Kirlioglu (19)      | Within 24 h of hospitalization or on admission of outpatient unit | Not specified | Not specified | Not specified | Not specified |
| Bustan et al. (20)                | Within 3 days of admission      | Not specified | Not specified | Not specified | Not specified |
| Kovács et al. (21)                | Not specified                   | Not specified | Not specified | Not specified | Not specified |
| Kulaksızoglu and Kulaksızoglu (22)| Not specified                   | 12 h of fasting | EDTA          | Not specified | Automated hematology analyzer (Beckman Coulter LH 780, Beckman Coulter, Brea, CA, USA) |
| Núñez et al. (23)                 | 8:00–10:00 a.m.                 | Overnight fasting | Not specified | Not specified | Automated analyzer and if a measure was out of the normal range, cell count values were manually determined with microscopy |
| Semiz et al. (24)                 | 9:00 a.m.                       | 12 h of fasting | EDTA          | Not specified | Automated blood cell counter (Abbott CELL-DYN 3700, Abbott Diagnostics Division, Abbott Laboratories, Illinois, USA) |
| Stefanović et al. (25)           | 8:00–8:30 a.m., prior to antipsychotic medication | 12 h of fasting | Not specified | Not specified | Hematology analyzer ABX MICRO 60-OT (UK) |
| Steiner et al. (26)               | 8:00 a.m.                       | Overnight fasting | EDTA          | 1 h           | Automated blood cell counter (XN-3000 automated counter, Sysmex Corporation) |
| Zhou et al. (27)                  | Not specified                   | Not specified | Not specified | Not specified | Not specified |
| Yüksel et al. (28)                | Not specified                   | Not specified | Not specified | Not specified | Not specified |
| Zornilla et al. (29)              | At admission                    | Not specified | Not specified | Not specified | Automated impedance cell counter (Coulter Electronics, FL) |
| Arif Önder et al. (30)            | Not specified                   | Not specified | Not specified | Not specified | Not specified |
| Özdin and Böke (31)               | Within 2 days of admission      | Not specified | Not specified | Not specified | Not specified |
TABLE 3 | Findings of neutrophil count and NLR in relation to diagnosis, antipsychotic medication, and state of the disease.

| Study focus                  | Study design                        | Neutrophil counts | NLR                  | References |
|------------------------------|-------------------------------------|-------------------|----------------------|------------|
| Relation to diagnosis        | Cross-sectional                      | FEP > HC          | FEP > HC             | (23)       |
|                              | Cross-sectional                      | FEP > HC          | FEP > HC             | (23)       |
|                              | Cross-sectional                      | FEP > HC          | EOS > HC             | (26)       |
|                              | Cross-sectional                      | EOS > HC          | EOS > HC             | (30)       |
| Effect of medication         | Cross-sectional                      | Drug-naive FEP = drug-free SCZ | Drug-naive FEP = drug-free SCZ | (26) |
|                              | Cross-sectional                      | Drug-free SCZ = medicated SCZ | Medicated SCZ = drug-free SCZ | (24) |
|                              | Cross-sectional                      | Drug-free SCZ = medicated SCZ | Medicated SCZ = drug-free SCZ | (31) |
|                              | Cross-sectional                      | Drug-free SCZ > medicated SCZ | Medicated SCZ < drug-free SCZ | (27) |
| Association with state of disease | Longitudinal                      | Before treatment > after treatment in FEP | Short-term > long-term antipsychotic treatment in SCZ | (21) |
|                              | Longitudinal                        | Relapse > remission | Positive correlation with PANSS-T | (23) |
|                              | Cross-sectional                      | Relapse = remission | Positive correlation with PANSS-T | (23) |
|                              | Cross-sectional                      | Positive correlation with PANSS-T | Positive correlation with PANSS-T | (23) |
|                              | Cross-sectional                      | Positive correlation with PANSS-T | NS correlation with BPRS | (24) |
|                              | Cross-sectional                      | Positive correlation with PANSS-T | NS correlation with PANSS-T | (24) |
|                              | Cross-sectional                      | Drug-free: Positive correlation with CGI-S and BPRS-T, Medicated: Negative correlation with BPRS-N | NS correlation with PANSS-T | (30) |
|                              | Longitudinal                        | Correlation between NLR at intake and reduction in SAPS | NS correlation with PANSS-T | (29) |

EOS, early-onset schizophrenia; FEP, first episode psychosis; HC, healthy controls; SCZ, schizophrenia; NS, not significant; PANSS-T, Positive and Negative Syndrome Scale–Total, SANS, The Scale for the Assessment of Negative Symptoms; SAPS, The Scale for the Assessment of Positive Symptoms. Significant differences are shown in bold.

PANSS negative subscale, although one study reported a negative correlation between NLR and BPRS negative symptoms score in medicated patients (27).

The observed association between neutrophils and symptoms burden is interesting. High neutrophil numbers and NLR is not a specific feature of schizophrenia but has been reported in many psychiatric diagnoses, including bipolar disorder, depression, and obsessive compulsive disorder (33–36). Stress is a trigger for mental illness and can cause increased release of neutrophils from the bone marrow by the effect of stress hormones (37, 38). How increased peripheral neutrophils relate to psychiatric disorders is less well-understood, but it may involve IL-1β-mediated neutrophil invasion and modulation of signaling in the brain [reviewed by (47)].

Since leukocyte levels fluctuate throughout the day, the time of blood sampling in essential when comparing white blood cell levels (39–41). The observed differences in leukocytes between schizophrenia patients and healthy controls in the included articles were of small magnitude, comparable to the difference seen throughout a day (42). Also the fasting status is important when comparing blood cell counts, as neutrophil count has been shown to increase after food intake while lymphocyte count decrease (32).

It is therefore a notable weakness in the literature that the description of the blood sampling procedure is often lacking
in the articles, which is quite surprising when this is a major source of potential technical and biological bias. Only four studies reported the blood sampling time and only five studies informed that the study participants were fasting before blood draw. Only one study specified that antipsychotic therapy was not initiated at the time of blood sampling. In addition to this, very few studies contained information on the technical equipment or the laboratory analytical procedure of blood sampling, which allow for possible unrepresentative comparisons between and within the different studies. Neutrophils are fragile cells, and the count may be influenced by methodological variables. A recent study concluded that the neutrophil count was significantly reduced at 1 h after blood draw and when stored at room temperature (43). This study found no effect of blood collection technique and anticoagulant. However, another study showed that neutrophils were better preserved in EDTA compared to heparin and citrate (44). Automated hematology analysers and manual counts by microscopy seem to give quite comparable results, but differ in the count of immature cells (45).

The strengths and limitations of this scoping review are mainly defined by the included studies. The studies were similar with respect to inclusion/exclusion criteria for study participants. Inclusion criteria were usually schizophrenia as defined in the DSM-IV/V or ICD-10. Exclusion criteria included a list of factors or diseases that could trigger an inflammatory response, but with variation in which diseases that were included, and some were brief in the description. There were limited relevant articles available, and the studies were conducted in various ways, with differences in recruitment of study participants, duration of observation, and outcome of interest. In addition, there was large variation in the number of study participants, ranging from 22 to 1144. The number of participants and the study design are important factors when evaluating the strength of the results. Longitudinal studies are more powerful and can help to determine cause and effect relationships, while retrospective studies have more bias and need larger numbers to detect significant differences.

Another challenge when comparing different studies, concerns the patient’s medication status. In the articles included in this review, different labels and definitions were used to describe the antipsychotic drug history. Several studies had no information about medication status at all. Among the patients labeled as “medicated,” only one study did comparisons based on length of treatment. None of the studies evaluated recent adherence to antipsychotic therapy. Medication compliance in schizophrenia is a constant challenge, with some studies reporting medication non-adherence to range from 20 to 89% (46). This highly variable compliance constitutes a considerable source of error when investigating antipsychotics effect on inflammatory parameters. Furthermore, the definition of being drug-free from antipsychotics varied. Two studies defined it as being off antipsychotics for more than 2 weeks, one study set the limit at 6 weeks, whereas one study did not specify any time frame. Although all antipsychotics have a half-life far below 2 weeks, it is not possible to exclude that hematological side-effects may persist even longer. Different subclasses of antipsychotics could potentially have different effects on neutrophils and lymphocytes. We also cannot rule out other confounding effects.

The scoping review methodology is also prone to its own limitations, such as the challenge to do a quality assessment. With studies of differing nature, comparisons, and weighting of results are difficult.

The trends identified in this article need to be validated. Firstly, the strength of the association between symptomatology and neutrophil count and NLR should be quantified. Furthermore, the time-course of neutrophil decrease after treatment should be further examined. Secondly, except for one study looking at granulocyte number, there are, to our knowledge, no studies comparing neutrophil count or NLR in responders vs. non-responders. It would be interesting to have studies that evaluate if this simple blood marker can be used to guide treatment of schizophrenia.

In this scoping review, we have a clear focus on methodological and technical issues that may influence the measurements of white blood cells. Further research should pursue standardized methods for blood sampling, ensuring identical timing of the procedure. The procedure should be done at the same time of day, and comparison groups should preferably be recruited in the same period/season. Factors that are known to increase leukocyte levels should be registered and accounted for, such as fasting and sleep disturbances. This would ensure more comparable and representative blood differentials and enhance our understanding of the immune system’s role in schizophrenia. Further studies should also investigate whether the elevated neutrophil count and NLR is only representative for a sub-group of psychotic patients and if these patients could have beneficial effect of anti-inflammatory treatment.

CONCLUSION

This scoping review investigated neutrophil count and NLR as cause or consequence of schizophrenia. We used a broad approach and included both longitudinal studies and studies with various comparison groups (medication, disease state, response, and symptoms) to identify potential causes of increased neutrophil numbers. In addition, we evaluated methodological and technical issues that may influence the measurements of blood cells.

We found that neutrophil count and NLR are increased in FEP and schizophrenia patients independent of antipsychotic use, compared to the healthy controls. A decrease in neutrophil count and NLR is reported after initiation of antipsychotic therapy, however, this may reflect an indirect effect of the parallel decrease of positive symptoms. There are substantial deficiencies in the available research, particularly concerning methodological standards and comparability of blood sampling procedures. Factors that affect the leukocyte count should be accounted for.
Further research should quantify the correlation between neutrophil count or NLR and symptomatology and investigate its clinical utility for monitoring the course of the disease.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

AS, VS, and AT conceptualized the project. AS and AT performed the literature screening and the review process. AS wrote the first draft of the manuscript. VS and AT critically reviewed the manuscript. All authors contributed to writing and revising the manuscript.

FUNDING

This work was supported by the Research Council of Norway (NORMENT CoE funding program; Grant No. 223273) and Helse Vest RHF, Norway (Grant No. F-12544)

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.728990/full#supplementary-material

REFERENCES

1. Brown AS, Derkits EI. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. (2010) 167:261–80. doi: 10.1176/appi.ajp.2009.0930361
2. Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB. Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res. (2012) 139:161–8. doi: 10.1016/j.schres.2012.05.023
3. Eaton WW, Byrne M, Ewald H, Mors O, Chen C-Y, Agerbo E, et al. Association of schizophrenia and autoimmune diseases: linkage of danish national registers. Am J Psychiatry. (2006) 163:521–8. doi: 10.1176/appi.ajp.163.3.521
4. Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. (2014) 511:412–7. doi: 10.1038/nature13595
5. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. (2016) 21:1696–709. doi: 10.1038/mp.2016.5
6. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. (2011) 70:663–71. doi: 10.1016/j.biopsych.2011.04.013
7. Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses. (2014) 7:223–30. doi: 10.3371/CSRP.MICU.020813
8. Jackson AJ, Miller BJ. Meta-analysis of total and differential white blood cell counts in schizophrenia. Acta Psychiatr Scand. (2020) 142:18–26. doi: 10.1111/acps.13140
9. Karageorgiou V, Milas GP, Michopoulos I. Neutrophil-to-lymphocyte ratio in schizophrenia: a systematic review and meta-analysis. Schizophr Res. (2019) 206:4–12. doi: 10.1016/j.schres.2018.12.017
10. Mazza MG, Lucci S, Rossetti A, Clerici M. Neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio and platelet-lymphocyte ratio in non-affective psychosis: a meta-analysis and systematic review. World J Biol Psychiatry. (2020) 21:326–38. doi: 10.15862/16629795.2019.1583371
11. Sanguineti MMM, Oliveira PH De, Martins-Filho A, Micheli DC, Tavares-Murta BM, Murta EFC, et al. Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol Invest. (2017) 46:677–88. doi: 10.1080/08822139.2017.1360342
12. Liu L, Yang F, Wang Y, Su S, Su Z, Jiang X, et al. Prognostic nomogram incorporating neutrophil-to-lymphocyte ratio for early mortality in decompensated liver cirrhosis. Int Immunopharmacol. (2018) 56:58–64. doi: 10.1016/j.intimp.2018.01.007
13. Du J, Liu J, Zhang X, Chen X, Yu R, Gu D, et al. Pre-treatment neutrophil-to-lymphocyte ratio predicts survival in patients with laryngeal cancer. Oncol Lett. (2018) 15:1664–72. doi: 10.3892/ol.2017.7501
14. Azab B, Zaheer M, Weisbergs KE, Torbey E, Lacossiere K, Gaddam S, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after NonST-elevation myocardial infarction. Am J Cardiol. (2010) 106:470–6. doi: 10.1016/j.amjcard.2010.03.062
15. Azab B, Bhatt VR, Phoakan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. (2012) 19:217–24. doi: 10.1245/s10434-011-1814-0
16. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. (2019) 169:467–73. doi: 10.7326/m18-0850
17. Distanzi M, Hamady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. (2016) 5:210. doi: 10.1186/s13643-016-0384-4
18. Page MJ, McKenzie JE, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 372:n71. doi: 10.1136/bmj.n71
19. Balcıoğlu YH, Kırlıoğlu SS. C-reactive protein/albumin and neutrophil/albumin ratios as novel inflammatory markers in patients with schizophrenia. Psychiatry Investig. (2020) 17:902–20. doi: 10.5487/pi.2020.0102
20. Bustan Y, Drapia A, Ben Dor DH, Avrahami M, Schwartz-Lifshitz M, Weizman A, et al. Elevated neutrophil to lymphocyte ratio in non-affective psychotic adolescent inpatients: evidence for early association between inflammation and psychosis. Psychiatry Res. (2018) 262:149–53. doi: 10.1016/j.psychres.2018.02.002
21. Kovács MÁ, Tényi T, Kugyelka R, Prenek L, Hau L, Magyar ÉE, et al. Elevated osteopontin and interferon gamma serum levels and increased neutrophil-to-lymphocyte ratio are associated with the severity of symptoms in schizophrenia. Front Psychiatry. (2020) 10:996. doi: 10.3389/fpsyt.2019.00996
22. Kulaksozgu B, Kulaksozgu S. Relationship between neutrophil/lymphocyte ratio with oxidative stress and psychopathology in patients with schizophrenia. Neuropsychiatr Dis Treat. (2016) 12:1999–2005. doi: 10.2147/NDT.S101484
23. Núñez C, Stephan-Otto C, Usall J, Bieboque M, Lobo A, González-Pinto A, et al. Neutrophil count is associated with reduced gray matter and enlarged ventricles in first-episode psychosis. Schizophr Bull. (2019) 45:846–58. doi: 10.1093/schbul/sby113
24. Semiz M, Yıldırım O, Canan F, Demir S, Hasbek E, Tuman TC, et al. Elevated neutrophil/lymphocyte ratio in patients with schizophrenia. Psychiatr Danub. (2014) 26:320–5.
25. Stefanović V, Mihajlović G, Nedanović M, Dejanović SD, Borovčanin M, Trajković G. The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia. Vojnosanit Pregl. (2015) 72:1085–92. doi: 10.2298/VSP140526016S
26. Steiner J, Frodl T, Schiltz K, Dobrowolny H, Jacobs R, Fernandes BS, et al. Innate immune cells and C-reactive protein in acute first-episode psychosis.
and schizophrenia: relationship to psychopathology and treatment. *Schizophr Bull.* (2020) 46:363–73. doi: 10.1093/schbul/bsb068

27. Zhou X, Wang X, Li R, Yan J, Xiao Y, Li W, et al. Neutrophil-to-lymphocyte ratio is independently associated with severe psychopathology in schizophrenia and is changed by antipsychotic administration: a large-scale cross-sectional retrospective study. *Front Psychiatry.* (2020) 11:581061. doi: 10.3389/fpsyt.2020.581061

28. Yüksel RN, Ertek IE, Dikmen AU, Göka E. High neutrophil-lymphocyte ratio in schizophrenia independent of infectious and metabolic parameters. *Nord J Psychiatry.* (2018) 72:336–40. doi: 10.1080/08039488.2018.1458899

29. Zorrelli EP, Cannon TD, Kessler J, Gur RE. Leukocyte differentials predict short-term clinical outcome following antipsychotic treatment in schizophrenia. *Biol Psychiatry.* (1998) 45:887–96. doi: 10.1016/s0006-3223(97)00358-2

30. Arif Örder, Adanir AS, Çoban ÖG, Bilacı Ö, Kavurmacı C. Elevated neutrophil/lymphocyte ratio in adolescents with early-onset schizophrenia. *Neurochem J.* (2020) 14:444–8. doi: 10.1134/s1819712420330016

31. Özdin S, Böke Ö. Neutrophil/lymphocyte, platelet/lymphocyte and monocyte/lymphocyte ratios in different stages of schizophrenia. *Psychiatry Res.* (2019) 271:131–5. doi: 10.1016/j.psychres.2018.11.043

32. Kościelnia BK, Charchut A, Wójcik M, Szetki K, Tomasik PJ. Impact of fasting on complete blood count assayed in capillary blood samples. *Lab Med.* (2017) 48:357–61. doi: 10.1093/labmed/lmx044

33. Özyurt G, Binici NC. The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in adolescent obsessive-compulsive disorder: does comorbid anxiety disorder affect inflammatory response? *Psychiatry Res.* (2019) 272:311–5. doi: 10.1016/j.psychres.2018.12.131

34. Mazza MG, Lucchi S, Tringali AGM, Rossetti A, Botti ER, Clerici M. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: a meta-analysis. *Prog Neuro Psychopharmacol Biol Psychiatry.* (2018) 84:229–36. doi: 10.1016/j.pnpbp.2018.03.012

35. Melo MCA, Garcia RF, de Araujo CFC, Abreu RLC, de Bruin VMS. Clinical significance of neutrophil-lymphocyte and platelet-lymphocyte ratios in bipolar patients: an 18-month prospective study. *Psychiatry Res.* (2019) 271:8–14. doi: 10.1016/j.psychres.2018.10.077

36. Özyurt G, Binici NC. Increased neutrophil-lymphocyte ratios in depressive adolescents is correlated with the severity of depression. *Psychiatry Res.* (2018) 268:426–31. doi: 10.1016/j.psychres.2018.08.007

37. Zieziulewicz TJ, Mondal TK, Gao D, Lawrence DA. Stress-induced effects, which inhibit host defenses, alter leukocyte trafficking. *Cell Stress Chaperones.* (2013) 18:279–91. doi: 10.1007/s12192-012-0380-0

38. Heidt T, Sager HB, Coutries G, Dutta P, Iwamoto Y, Zaltsman A, et al. Chronic variable stress activates hematopoietic stem cells. *Nat Med.* (2014) 20:754–8. doi: 10.1038/nm.3589

39. Ella K, Csépányi-Komi R, Káldi K. Circadian regulation of human peripheral neutrophils. *Brain Behav Immun.* (2016) 57:209–21. doi: 10.1016/j.bbi.2016.04.016

40. Casanova-Abcebes M, Pitaval C, Weiss LA, Nombela-Arrieta C, Chévre R, A-González N, et al. Rhythmic modulation of the hematopoietic niche through neutrophil clearance. *Cell.* (2013) 153:1025. doi: 10.1016/j.cell.2013.04.040

41. Oh G, Koncevićus K, Ebrahimi S, Carlucci M, Groot DE, Nair A, et al. Circadian oscillations of cytokine modification in humans contribute to epigenetic variability, aging, and complex disease. *06 Biological Sciences 0604 Genetics. Genome Biol.* (2019) 20:2. doi: 10.1186/s13059-018-1608-9

42. Wyse C, O’Malley G, Coogan AN, Smith DJ. Seasonal and daytime variation in multiple immune parameters in humans: evidence from 329,261 participants of the UK biobank cohort. *iScience.* (2021) 24. doi: 10.1016/j.isci.2021.102255

43. Krabbe J, Beilmann V, Almazad-Krabbe H, Boll S, Seifert A, Ruske N, et al. Blood collection technique, anticoagulants and storing temperature have minor effects on the isolation of polymorphonuclear neutrophils. *Sci Rep.* (2020) 10:14646. doi: 10.1038/s41598-020-71500-1

44. Freitas M, Porto G, Lima JLF, Fernandes E. Isolation and activation of human neutrophils in vitro. The importance of the anticoagulant used during blood collection. *Clin Biochem.* (2008) 41:570–5. doi: 10.1016/j.clinbiochem.2007.12.021

45. Siekmeier R, Bierlich A, Jaroß W. The white blood cell differential: three methods compared. *Clin Chem Lab Med.* (2001) 39:432–45. doi: 10.1515/CCLM.2001.069

46. Barkhof E, Meijer CJ, de Sonneville LMJ, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-a review of the past decade. *Eur Psychiatry.* (2012) 27:9–18. doi: 10.1016/j.eurpsy.2011.02.005

47. Pfleger FJ, Hernandez J, Schweighöfer H, Herden C, Rosengarten B, Rummel C. The role of neutrophil granulocytes in immune-to-brain communication. *Temperature.* (2018) 5:296–307. doi: 10.1080/23328940.2018.1538598

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Sandberg, Steen and Torsvik. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.